Amgen Receives “Market Perform” Rating from Leerink Swann (AMGN)
Amgen (NASDAQ:AMGN)‘s stock had its “market perform” rating restated by equities researchers at Leerink Swann in a research report issued on Wednesday, AnalystRatingsNetwork reports. They currently have a $128.00 price target on the stock. Leerink Swann’s target price would indicate a potential upside of 11.71% from the company’s current price.
A number of other analysts have also recently weighed in on AMGN. Analysts at BMO Capital Markets raised their price target on shares of Amgen (NASDAQ:AMGN) from $108.00 to $116.00 in a research note to investors on Tuesday, September 24th. They now have a “market perform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Amgen (NASDAQ:AMGN) in a research note to investors on Friday, September 13th. They now have a $119.00 price target on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Amgen (NASDAQ:AMGN) in a research note to investors on Monday, September 9th. Eleven investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $117.96.
Amgen (NASDAQ:AMGN) traded down 1.59% on Wednesday, hitting $112.76. 671,382 shares of the company’s stock traded hands. Amgen has a 52-week low of $81.56 and a 52-week high of $117.91. The stock has a 50-day moving average of $111.2 and a 200-day moving average of $105.5. The company has a market cap of $84.948 billion and a P/E ratio of 19.31.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 30th. The company reported $1.89 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.74 by $0.15. The company had revenue of $4.68 billion for the quarter, compared to the consensus estimate of $4.49 billion. During the same quarter last year, the company posted $1.83 earnings per share. Amgen’s revenue was up 4.5% compared to the same quarter last year. Analysts expect that Amgen will post $7.27 EPS for the current fiscal year.
Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.